Back to search
FDAFDA · Food and drugs·Recall number D-0087-2023

Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

Published December 28, 2022 · Recall initiated: December 16, 2022

Summary

FDA records drug Class II recall D-0087-2023, published December 28, 2022 and initiated December 16, 2022. Recalling firm: Aurolife Pharma, LLC; Status: Ongoing; Reported quantity: 7344 bottles; Lot: Lots: 01422002A1, Expiry: 12/2023; 01421078A3, Expiry: 09/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated

Get an email if GLYCOPYRROLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GLYCOPYRROLATE
Manufacturer
Aurolife Pharma, LLC
Distributor
Nationwide in the USA and Puerto Rico.
UPC
0313107014017
Lot
Lots: 01422002A1, Expiry: 12/2023; 01421078A3, Expiry: 09/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01 recalled?

Yes. FDA published recall D-0087-2023 on December 28, 2022. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GLYCOPYRROLATE. UPC: 0313107014017.